Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-10
2006-10-10
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S049000, C514S050000, C514S256000, C536S028200, C536S028540, C536S028530, C536S028550, C544S309000, C544S313000
Reexamination Certificate
active
07119096
ABSTRACT:
Uracil reductase inactivators, notably a 5-substituted uracil or 5,6-dihydro-5-substituted uracil, potentiate 5-flourouracil and find use particularly in the treatment of cancer. The 5-substituent is selected from bromo, ido, cyano, halo-substituted C1-4alkyl, C2-6alkenyl, 1-halo-C2-6alkenyl and halo-substituted C2-6alkynyl.
REFERENCES:
patent: 4124765 (1978-11-01), Kurono et al.
patent: 4381344 (1983-04-01), Rideout et al.
patent: 4719214 (1988-01-01), Shealy et al.
patent: 4863927 (1989-09-01), Tolman et al.
patent: 5079235 (1992-01-01), Purifoy et al.
patent: 5157114 (1992-10-01), Rahim et al.
patent: 5198539 (1993-03-01), Rahim et al.
patent: 5643913 (1997-07-01), Spector et al.
patent: 6177436 (2001-01-01), Spector et al.
patent: 6221852 (2001-04-01), Spector et al.
patent: 6268374 (2001-07-01), Spector et al.
patent: 6586440 (2003-07-01), Spector et al.
patent: 2522369 (1988-11-01), None
patent: 0272065 (1988-06-01), None
patent: 0337599 (1989-10-01), None
patent: 0356166 (1990-02-01), None
patent: 0371139 (1990-06-01), None
patent: 0409575 (1991-02-01), None
patent: 89/09603 (1989-10-01), None
patent: 92/01452 (1992-02-01), None
International Search Report and Annex thereto for International Application No. PCT/GB91/01650 mailed Jan. 8, 1992.
Parker, W.B. et al., “Metabolism and Mechanism of Action of 5-Fluorouracil”, Pharmacol. and Ther., 48, 381-395 (1990).
Fardos N.M. Naguib et al., Structure-Activity Relationship of Ligands of Dihydrouracil Dehydrogenase from Mouse Liver:, Biochemical Pharmacology, 38(9), 1471-1480 (1989).
Masaaki Iigo et al, “Enhancing Effect of Bromovinyldeoxyridine on Antitumor Activity of 5'-Deoxy-5-Fluorouridine Against Adenocarcinoma 755 in Mice”, Biochemical Pharmacology, 38(12), 1885-1889 (1989).
Thornburng, Lora d. et al., “Mechanism-Based Inhibition of thymine Hydroxylase”, J. American Chemical Society, 111, 7632-7633 (1989).
Kunigiko Tatsumi et al., “Inhibitory Effects of Pyrimidine, Barbituric Acid and Pyridine Derivatives on 5-Fluorouracil Degradation in Rat Liver Extracts”, Japan J. Cancer Research (Gann), 78, 748-755 (1987).
Tuchman, M. et al., Chemical Abstracts, 104:14633m (1986).
Desgranges, C. et al., “Effect of (E)-5-(l-Bromovinyl)uracil on the Catabolism and Antitumor Activity of 5-Fluorouracil in Rats and Leukemic Mice”, Cancer Research, 46, 1094-1101 (1986).
Ho, D.H. et al., “Distribution and Inhibition of Dihydrouracil Dehydrogenase Activities in Human Tissues Using 5-Fluorouracil as a Substrate”, Anticancer Research, 6(4), 781-784, (1986).
Fujii, S. et al., “Cancer—chemotherapy with 5-fluorouracil and its derivatives”, Int. Congr. Ser.-Excerpta Med., 729 Cancer Chemotherapy: Challenges Future, 117-25 (1986).
Chu, M.Y. W. et al., “Potentiation of 5 Fluoro-2'-deoxy Uridine Anti Neoplastic Activity by the Uridine Phospohorylase Inhibiitors Benzyl Acyclo uridine and Benzyloxybenzyl Acyclo Uridine”, Cancer Research, 4(5), 1852-1856 (1984).
Farka{hacek over (s)}, Jirí, “Synthesis of 1,2,4-Triazine-3,5 (2H, 4H)-Diones Containing Electonegative Substituents in Position 6”, Collection Czechoslovak Chem. Commun., 48(9), 2676-2681 (1983).
Robins, Morris J. et al., “Nucleic Acid Related Compounds. 393 Efficient Conversion of 5-Iodo to 5-Alkynyl and Derived 5-Substituted Uracil Bases and Nucleosides”, J. Organic Chemistry, 48(11), 1854-62 (1983).
Kundu, Nitya G. et al., “Studies on Uracil Derivatives and Analogs. Synthesis of 5- (β-Trimethylsilyl)ethynyluracil and 5- Ethynyluracil”, J. Heterocyclic Chem., 19(3), 463-4 (1982).
Robins, Morris J. et al., “Nucleic Acid Related Compounds. 38. Smooth and high-yield iodination and chlorination at C-5 of uracil bases and p-toluyl-protected nucleosides”, Canada J. Chemistry, 60(5), 554-7 (1982).
Barr, Phillip J. et al., “Synthesis of Some 5-halogenovinyl Derivatives of Uracil and their Conversion into 2'-Deoxyribonucleosides”, J. Chemical Society Perkin Trans., 1(16), 1665-70 (1981).
Krenitsky, T.A. et al., “Purine Nucleoside Synthesis, as Efficient Method Employing Nucleoside Phosphorylases”, Biochemistry, 20, 3615-3621 (1981).
Robins, Morris J. et al., Nucleic Acid Related Compounds. 31. Smooth and Efficient Palladium-Copper Catalyzed Coupling of Terminal Alkynes with 5-Iodouracil Nucleosides, Tetrahedron let., 22(5), 421-424, (1981).
Bleackley, R.C. et al., “Replacement of the Iodine Atom of 5-Iodouracil by the 5-Cyano Group”, Nucleic Acid Chemistry, vol. 2, 927-930, (1978).
Hein, L. et al., “Preparation of 5-Trifluoromethyluracil”, Z. Chem., 17(11), 415-416, (1977) (Translation).
Barr, P.J. et al., “Incorporation of 5-substituted uracil derivatives into nucleic acids. Part IV. The Synthesis of 5-ethynyluracil”, Nucleic Acids Research, 3(10), 2845 (1976).
Jones, A.S. et al., “A method for the rapid preparation of 5-vinyluracil in high yield”, Nucleic Acids Research, 1(1), 105-107, (1974).
Calabresi, et al,Initial Clinical Studies with 5-Iodo-2'deoxyuridine, Cancer Research, May 1961, vol. 21, pp. 550-559.
Berry, et al.,Modification of Radiation Effect on Mammalian Tumor Cells by Pharmacological Agents,Nature, Oct. 13, 1962, No. 4850, vol. 196, pp. 185-186.
Erikson; et al.,Molecular Radiobiology of Human Cell Lines,Cancer Research, Jan. 1963, vol. 23, pp. 122-130.
Erikson, et al.,Molecular Radiobiology of Human Cell Lines V. Comparitive Radiosenstitizing Properties of 5-Halodeoxy-cytidines and 5-Halodeoxyuridines,Radiation Research, 1963, vol. 20, pp. 252-262.
Szybalski, W.,X-Ray Sensitization by Halopyrimidines, Cancer Chemotherapy Reports, Jul./Aug. 1974, Part 1, vol. 58 No. 4, pp. 539-557.
Abstract: Desranges, C.,Chemical Abstracts, 104:178920, (1986).
Abstract: Ho, Dah Hsi,Chemical Abstracts, 105:183337, (1986).
Bobek, et al.,The Chemistry and Biology of Some New Nucleoside Analogs Active Against Tumor Cells, Chemistry and Biology of Nucleosides and Nucleotides, pp. 135-149 (1978).
Jones, et al.,The Preparation and Properties of Some 5-Substituted Uracil Derivatives, Nucleic Acids Research, Spec. Pub. No. 1, pp. s1 & s4. (1975).
Sharma, et al.,Acetylenic Nucleosides. 3. Synthesis and Biological Activities of Some 5-Ethynylpyrimidine Nucleosides, Journal of Medicinal Chemistry, 1984, vol. 27, No. 3, pp. 410-412.
Porter David J. T.
Rahim Saad G.
Spector Thomas
Coulter Kathryn L.
Lemanowicz John L.
O'Sullivan Peter
SmithKlineBeecham Corporation
LandOfFree
Uracil reductase inactivators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uracil reductase inactivators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uracil reductase inactivators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3664994